Shanghai OPM Biosciences Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Shanghai OPM Biosciences (SHSE:688293) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥243.1m (down 17% from FY 2022).
• Net income: CN¥54.0m (down 49% from FY 2022).
• Profit margin: 22% (down from 36% in FY 2022).
• EPS: CN¥0.47 (down from CN¥1.10 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai OPM Biosciences Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 14%.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 17% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Shanghai OPM Biosciences has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.